Hyponatremia in acute heart failure syndromes: A potential therapeutic target

Current Heart Failure Reports

Volumn 4, Issue 4, 2007, Pages 207-213

  Brandimarte, Filippo ^b   Fedele, Francesco ^b   De Luca, Leonardo ^b   Fonarow, Gregg C ^b   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MILRINONE; PLACEBO; SODIUM; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN ANTAGONIST;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG DOSE TITRATION; HEART FAILURE; HUMAN; HYPONATREMIA; MORBIDITY; MORTALITY; REVIEW; SYSTOLIC BLOOD PRESSURE;

HEART FAILURE; HUMANS; HYPONATREMIA; SODIUM; SURVIVAL RATE; TREATMENT OUTCOME; VASOPRESSINS;

EID: 38049039835     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0014-5     Document Type: Review

References (25)

1. Upadhyay A, Jaber BL, Madias NE: Incidence and prevalence of hyponatremia. Am J Med 2006, 119:S30-S35.
2. Martin-Llahi M, Guevara M, Gines P: Hyponatremia in cirrhosis: clinical features and management. Gastroenterol Clin Biol 2006, 30:1144-1151.
3. Goldberg A, Hammerman H, Petcherski S, et al.: Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 2006, 166:781-786.
4. Lien YH, Shapiro JI: Hyponatremia: clinical diagnosis and management. Am J Med 2007, 120:653-658.
5. Fonarow GC, Abraham WT, Albert NM, et al.: Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. Am Heart J 2004, 148:43-51.
6. Gheorghiade M, Abraham WT, Albert NM, et al.: Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur Heart J 2007, 28:980-988. This retrospective analysis provided important information for the characterization and prognosis of patients with hyponatremia.
7. Rich MW, Beckham V, Wittenberg C, et al.: A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995, 333:1190-1195.
8. Lee DS, Austin PC, Rouleau JL, et al.: Predicting mortality among patients hospitalized for heart failure: derivation and validation for a clinical model. JAMA 2003, 290:2581-2587.
9. Cuffe MS, Califf RM, Adams KF, Jr, et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002, 287:1541-1547.
10. Klein L, O'Connor CM, Leimberger JD, et al.: Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 2005, 111:2454-2460. This retrospective analysis contributed to the recognition of hyponatremia as an important prognostic factor in HF.
11. Binanay C, Califf RM, Hasselblad V, et al.: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005, 294:1625-1633.
12. Gheorghiade M, Rossi JS, Cotts W, et al.: Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007, 167:1998-2005. This retrospective analysis showed that persistent hyponatremia is associated with higher mortality and rehospitalization rates.
13. Gheorghiade M, Gattis WA, O'Connor CM, et al.: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004, 291:1963-1971.
14. Rossi J, Bayram M, Udelson JE, et al.: Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. Acute Card Care 2007, 9:82-86.
15. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
16. Riegger GAJ, Liebau G, Kochsiek K: Antidiuretic hormone in congestive heart failure. Am J Med 1982, 72:49-52.
17. Goldsmith SR: Vasopressin: a therapeutic target in congestive heart failure? J Card Fail 1999, 5:347-356.
18. Goh KP: Management of hyponatremia. Am Fam Physician 2004, 69:2387-2394.
19. Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006, 355:2099-2112.
20. Gheorghiade M, Gottlieb SS, Udelson JE, et al.: Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006, 97:1064-1067.
21. Gheorghiade M, Niazi I, Ouyang J, et al.: Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003, 107:2690-2696.
22. 2 vasopressin antagonism in heart failure.
23. 2 vasopressin antagonism in heart failure.
24. Zeltser D, Rosansky S, van Rensburg H, et al.: Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007, 27:447-457.
25. Ghali JK, Koren MJ, Taylor JR, et al.: Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006, 91:2145-2152.